Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Support, Treatment, and Overdose Prevention of Fentanyl Act of 2021 or the STOP Fentanyl Act of 2021 This bill addresses data collection, treatment, harm reduction, and other issues related to substance misuse and addiction. It particularly focuses on opioids, fentanyl, and related substances. Specifically, the bill expands surveillance of fentanyl and related substances. This includes establishing a pilot program to screen for contaminants in illicit drugs and a grant program to collect data on fentanyl-involved overdoses. The bill also specifies requirements concerning the collection and use of information about drugs seized by law enforcement. Additionally, the bill establishes and modifies requirements to increase access to treatment and prevention services. For example, the Bureau of Prisons must make certain services, including medication-assisted treatments, available to individuals in its custody. The bill also repeals a provision that requires dependence on opioids for at least one year before an individual may be admitted to certain treatment programs; allows providers to prescribe medications to treat substance use disorders following a telehealth evaluation; creates grant programs for treatment and harm reduction activities; and addresses issues pertaining to opioid overdose reversal drugs. Furthermore, the bill limits civil and criminal liability under specified laws for individuals who administer opioid overdose reversal drugs to an individual who reasonably appears to be experiencing an overdose, as well as for individuals who seek medical attention for themselves or on behalf of another for a drug overdose. The bill also requires multiple reports, including a report by the Department of State on foreign sources of certain drugs.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (13)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2023 · third_quarter · Budget/Appropriations
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress); H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (PL 117-328) and FY24 appropriations bills; Further Extending Government Funding Act (PL 117-70); Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2023 · second_quarter · Budget/Appropriations
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Client expense: Not reported · Firm income: $60,000
2023 · first_quarter · Budget/Appropriations
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Client expense: Not reported · Firm income: $60,000
2022 · second_quarter · Health Issues
Lobbied for $69.5 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Lobbying to pass a fentanyl harm reduction bill called the STOP Fentanyl Act (HR 2366/S 1457) which emphasizes expanding access to health services for people who use drugs.
Client expense: $87,644 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
State Opioid Response Grants funding Substance Abuse and Mental Health Block Grant funding CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R. 2379 The State Opioid Response Grant Authorization Act of 2021 H.R 2366/S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| OR |
| Sheldon Whitehouse | Democratic | RI |
| Tammy Baldwin | Democratic | WI |
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · fourth_quarter · Disaster Planning/Emergencies
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone HR 2617 - Consolidated Appropriations Act, 2023 (Omnibus) HR 1437 - Further Continuing Appropriations and Extensions Act State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Homeland Security
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone HR 2617 - Consolidated Appropriations Act, 2023 (Omnibus) HR 1437 - Further Continuing Appropriations and Extensions Act State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Budget/Appropriations
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone HR 2617 - Consolidated Appropriations Act, 2023 (Omnibus) HR 1437 - Further Continuing Appropriations and Extensions Act State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Budget/Appropriations
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.2617 - Consolidated Appropriations Act, 2023 (Omnibus) H.R.1437 - Further Continuing Appropriations and Extensions Act State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341; S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366; S.1457 - Stop Fentanyl Act H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $640,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · fourth_quarter · Disaster Planning/Emergencies
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.2617 - Consolidated Appropriations Act, 2023 (Omnibus) H.R.1437 - Further Continuing Appropriations and Extensions Act State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341; S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366; S.1457 - Stop Fentanyl Act H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $640,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · fourth_quarter · Health Issues
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.2617 - Consolidated Appropriations Act, 2023 (Omnibus) H.R.1437 - Further Continuing Appropriations and Extensions Act State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341; S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366; S.1457 - Stop Fentanyl Act H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $640,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
2022 · fourth_quarter · Homeland Security
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.2617 - Consolidated Appropriations Act, 2023 (Omnibus) H.R.1437 - Further Continuing Appropriations and Extensions Act State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341; S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366; S.1457 - Stop Fentanyl Act H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $640,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · fourth_quarter · Budget/Appropriations
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · third_quarter · Disaster Planning/Emergencies
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone HR 6833 - House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Budget/Appropriations
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone HR 6833 - House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Homeland Security
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone HR 6833 - House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
State Opioid Response Grants funding Substance Abuse and Mental Health Block Grant funding CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R. 2379 The State Opioid Response Grant Authorization Act of 2021 H.R 2366/S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Budget/Appropriations
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · third_quarter · Health Issues
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341/S.987 - CARA 3.0 Act of 2021 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366/S.1457 - STOP Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
2022 · third_quarter · Homeland Security
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341/S.987 - CARA 3.0 Act of 2021 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366/S.1457 - STOP Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · third_quarter · Budget/Appropriations
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341/S.987 - CARA 3.0 Act of 2021 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366/S.1457 - STOP Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · third_quarter · Disaster Planning/Emergencies
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R.4341/S.987 - CARA 3.0 Act of 2021 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R.2366/S.1457 - STOP Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · second_quarter · Health Issues
H.R. 1475/S.1795 Pursuing Equity in Mental Health Act S. 660/H.R. 2264: Tele-Mental Health Improvement Act H.R. 1364: Parity Enforcement Act S. 2086: The Resilience Investment, Support and Expansion (RISE) from Trauma Act S. 1927: Child Abuse Prevention and Treatment Act (CAPTA) Reauthorization of 2021 H.R 3467: Improving Data Collection for Adverse Childhood Experiences (ACEs) Act H.R. 1385: Behavioral Health Coordination and Communication Act S. 445: Mainstreaming Addiction Treatment Act S. 854: Methamphetamine Response Act S. 1457: STOP Fentanyl Act S. 1962/H.R. 3753: Parity Implementation Assistance Act Draft Global Enhancement of Mental Health and Psychosocial Support Access Act of 2021 H.R. 5218: Collaborate in an Orderly and Cohesive Manner Act S.2873 - Preventing and Addressing Trauma with Health Services (PATHS) Act Draft Reconciliation package Future Senate Finance Committee mental health legislation Future Cures 2.0 legislation from Rep. DeGette and Rep. Upton Draft Child Abuse and Neglect Data Collection and Improvement Act of 2021 Draft Legislation to award grants to 10 eligible crisis centers to provide follow-up services to individuals receiving suicide prevention and crisis intervention services (Rep. Trone) Coalition letter to state governors re: emergency temporary licensure waivers for out-of-state practitioners H.R. 5848 / S. 3149: Rural Health Equity Act Draft legislation to support reimbursement for psychology interns and residents in Medicare Draft legislation to support the reauthorization of Title VII programs H.R. 4026 Social Determinants of Health Data Analysis Act of 2021 H.R. 3894 CARING for Social Determinants Act of 2021 H.R. 3173 / S. 3018 Improving Seniors Access to Timely Care Act H.R. 7116 988 Implementation Act Draft bereavement care bill Letter to CDC re: Office of Rural Health Coalition thank-you letter to Congressional leadership and White House re: omnibus package S. 4301 Substance Use Prevention, Treatment, and Recovery Act S. 4306 Improving Access to Behavioral Health Integration Act S.4170 Mental Health Reform Reauthorization Act S.3824/H.R. 7073 Into the Light for MMH and SUD Act of 2022 H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022 H.R. 2955/ S. 4448 Suicide Prevention Act
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · second_quarter · Health Issues
H.R. 1475/S.1795 Pursuing Equity in Mental Health Act S. 660/H.R. 2264: Tele-Mental Health Improvement Act H.R. 1364: Parity Enforcement Act S. 2086: The Resilience Investment, Support and Expansion (RISE) from Trauma Act S. 1927: Child Abuse Prevention and Treatment Act (CAPTA) Reauthorization of 2021 H.R 3467: Improving Data Collection for Adverse Childhood Experiences (ACEs) Act H.R. 1385: Behavioral Health Coordination and Communication Act S. 445: Mainstreaming Addiction Treatment Act S. 854: Methamphetamine Response Act S. 1457: STOP Fentanyl Act S. 1962/H.R. 3753: Parity Implementation Assistance Act Draft Global Enhancement of Mental Health and Psychosocial Support Access Act of 2021 H.R. 5218: Collaborate in an Orderly and Cohesive Manner Act S.2873 - Preventing and Addressing Trauma with Health Services (PATHS) Act Draft Reconciliation package Future Senate Finance Committee mental health legislation Future Cures 2.0 legislation from Rep. DeGette and Rep. Upton Draft Child Abuse and Neglect Data Collection and Improvement Act of 2021 Draft Legislation to award grants to 10 eligible crisis centers to provide follow-up services to individuals receiving suicide prevention and crisis intervention services (Rep. Trone) Coalition letter to state governors re: emergency temporary licensure waivers for out-of-state practitioners H.R. 5848 / S. 3149: Rural Health Equity Act Draft legislation to support reimbursement for psychology interns and residents in Medicare Draft legislation to support the reauthorization of Title VII programs H.R. 4026 Social Determinants of Health Data Analysis Act of 2021 H.R. 3894 CARING for Social Determinants Act of 2021 H.R. 3173 / S. 3018 Improving Seniors Access to Timely Care Act H.R. 7116 988 Implementation Act Draft bereavement care bill Letter to CDC re: Office of Rural Health Coalition thank-you letter to Congressional leadership and White House re: omnibus package S. 4301 Substance Use Prevention, Treatment, and Recovery Act S. 4306 Improving Access to Behavioral Health Integration Act S.4170 Mental Health Reform Reauthorization Act S.3824/H.R. 7073 Into the Light for MMH and SUD Act of 2022 H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022 H.R. 2955/ S. 4448 Suicide Prevention Act
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · second_quarter · Homeland Security
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Budget/Appropriations
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Disaster Planning/Emergencies
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 HR 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Disaster Planning/Emergencies
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone House and Senate appropriations for FY 2023 H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 HR 7681 - Preventing Overdoses and Saving Lives Act 2.0 S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2022 · second_quarter · Health Issues
State Opioid Response Grants funding Substance Abuse and Mental Health Block Grant funding CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R. 2379 The State Opioid Response Grant Authorization Act of 2021 H.R 2366/S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S. 3799 - PREVENT Pandemics Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This Program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities. Advocated for increased appropriations for HRSAs Integrated Substance Use Disorder Training Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. Advocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting underrepresented minority addiction medicine professionals, including SAMHSAs Minority Fellowship Program. Advocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and standards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings. Advocated for H.R.7803 - Michelle Alyssa Go Act, which would amend title XIX of the Social Security Act to remove the exclusion from medical assistance under the Medicaid program of items and services for patients in an institution for mental diseases, and for other purposes. Advocated for use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant and acceptance of Medicaid by treatment grantees. Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so. Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers. Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who are incarcerated, during the 30-day period preceding their release from jail or prison. Advocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which would repeal the inmate exclusion that bars the use of federal Medicaid matching funds from covering health care services in jails and prisons. Advocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of 2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates. Advocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels. Advocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA. Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares continued ability, beyond the COVID-19 public health emergency, to reimburse for audio-only, SUD and mental health telehealth services after an in-person or telehealth evaluation. Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD. Advocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment. Advocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. Advocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment: Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating Kickbacks in Recovery Act Civil, as they may be applied to the implementation of contingency management (CM) for the treatment of addiction. Approval of a prescription to over the counter (OTC) switch for at least one naloxone product. This change would save lives and reduce existing barriers that prevent access to this critical medication; Regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet level of care standards set forth in The ASAM Criteria; Regulatory (or legislative) changes that would allow pharmacy dispensing and/or administration of methadone that has been prescribed by a legally authorized prescriber of controlled medications who is affiliated with an OTP or is a board-certified addiction specialist physician; Regulatory (or legislative) changes that would make permanent the opioid treatment program (OTP) flexibilities, including the methadone unsupervised dosing flexibilities, implemented during the COVID-19 Public Health Emergency while continuing study of the impact of these flexibilities; Assessment of current opioid order systems and monitoring programs to more fully understand the potential negative implications for patient access to buprenorphine at pharmacies and other controlled substance medications used to treat OUD; Issuance of regulations relating to a special registration for telemedicine, as was directed in Section 3232 of the SUPPORT Act of 2018. Advocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package. Advocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers. Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs. Advocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. Supported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO). Supported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes. Joined advocacy efforts with Senate Committee on Finance, encouraging full extension of federal mental health and substance use disorder parity protections to Medicare, all of Medicaid, and TRICARE. Advocated for closer coordination among relevant federal agencies, greater integration between primary care and behavioral health reimbursement, and robust funding for the addiction treatment workforce-- such as the Addiction Medicine Fellowship Program. ASAM also expressed support for legislation to ensure state compliance with mental health and addiction parity law and codification of audio-video telehealth prescribing flexibilities for the treatment of substance use disorder. Finally, ASAM called on federal legislators to consider new and promising strategies like contingency management Urged inclusion of the field of addiction medicine in reauthorizations of several SAMHSA programs as well as conveyed ways to improve clinician access to relevant addiction medicine education Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine. Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare. Advocated for federal agency guidance on CAPTA reporting vs. notification requirements. Advocated for stronger network adequacy requirements for OTPS and addiction specialist physicians under Medicare Advantage Plans On April 4, ASAM and stakeholders sent a letter to the House Energy & Commerce Committee in support the "Mental Health Justice and Parity Act of 2022," under consideration at the Committee's April 5 hearing. The organizations asked the Committee to support the legislation that phases out "parity opt-outs" among self-funded state and local health plans. On May 10th, ASAM sent a letter to leadership of the U.S. House Committee on Energy and Commerce on H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 (the Act), in advance of the Subcommittee on Healths legislative mark-up session on May 11th. In its letter, ASAM advocates for reducing complex barriers to addiction treatment, including eliminating the one-year requirement that an individual have an addiction to opioids to begin methadone treatment at an opioid treatment program (OTP), supporting provisions inspired by the Opioid Treatment Access Act (OTAA) - including revising who can determine the stability of a patient for take-homes to include a medical practitioner appropriately licensed by the State to prescribe or dispense controlled medications, - and codifying recent mobile methadone regulations into law. In its letter, ASAM also advocates for increased funding to support HRSAs Addiction Medicine Fellowship Program; adding addiction medicine to SAMHSAs Minority Fellowship Program grants, and adding addiction specialists to HRSAs Pediatric Mental Health Care Access grants. The letter concludes with a call for adding the MATE and MAT Acts to the Act. The MATE Act would condition the federal DEA registration to prescribe controlled medications on a one-time, flexible education requirement on the treatment of patients with substance use disorder. The MAT Act would eliminate the DATA 2000-waiver, a barrier to broader uptake of treatment for OUD with buprenorphine, a life-saving medication. On April 1, ASAM joined a coalition letter to the Department of Labor and HHS expressing concern about a recent decision from a three-judge panel of the U.S. Ninth Circuit Court of Appeals that threatens to have devastating effects on Americans ability to access medically necessary mental health and substance use disorder (MH/SUD) services covered by commercial health plans and requesting that the Departments of Labor and Health and Human Services file an amicus brief in this case to support en banc review before the entire Ninth Circuit. On May 11th, ASAM and other stakeholders sent a letter to U.S. House Energy and Commerce Committee leadership praising Section 321 of the Restoring Hope for Mental Health and Well-Being Act of 2022, which would sunset the ability of self-funded, non-federal governmental health care plans to opt-out of protections provided by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. On June 3, ASAM joined a large coalition of public health, harm reduction, HIV, and hepatitis organizations in sending a letter urging Congress to appropriate $150 million in fiscal year 2023 towards the Centers for Disease Control and Preventions (CDC) Infectious Diseases and Opioid Epidemic Program. This letter garnered support from 334 organizations from all fifty states, DC, and Puerto Rico, and may be the largest display of support from community stakeholders for lifesaving harm reduction services and for ending the ban on the use of certain federal funding for syringes. On June 14th, ASAM joined a coalition letter regarding the FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill, urging House appropriators not to include provisions that would weaken FDAs authority over tobacco products. On June 27th, ASAM joined a Coalition of Whole Health letter to Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and Deputy Administrator Dr. Meena Seshamani, supporting a proposed Medicare rule that would establish a special enrollment period (SEP) for individuals formerly incarcerated and exempt those who enroll under the SEP from a Late Enrollment Penalty (LEP) and urging CMS to revise its current definition of in custody for Medicare to be consistent with the definition CMS uses for Medicaid.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · second_quarter · Medicare/Medicaid
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This Program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities. Advocated for increased appropriations for HRSAs Integrated Substance Use Disorder Training Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. Advocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting underrepresented minority addiction medicine professionals, including SAMHSAs Minority Fellowship Program. Advocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and standards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings. Advocated for H.R.7803 - Michelle Alyssa Go Act, which would amend title XIX of the Social Security Act to remove the exclusion from medical assistance under the Medicaid program of items and services for patients in an institution for mental diseases, and for other purposes. Advocated for use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant and acceptance of Medicaid by treatment grantees. Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so. Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers. Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who are incarcerated, during the 30-day period preceding their release from jail or prison. Advocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which would repeal the inmate exclusion that bars the use of federal Medicaid matching funds from covering health care services in jails and prisons. Advocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of 2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates. Advocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels. Advocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA. Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares continued ability, beyond the COVID-19 public health emergency, to reimburse for audio-only, SUD and mental health telehealth services after an in-person or telehealth evaluation. Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD. Advocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment. Advocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. Advocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment: Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating Kickbacks in Recovery Act Civil, as they may be applied to the implementation of contingency management (CM) for the treatment of addiction. Approval of a prescription to over the counter (OTC) switch for at least one naloxone product. This change would save lives and reduce existing barriers that prevent access to this critical medication; Regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet level of care standards set forth in The ASAM Criteria; Regulatory (or legislative) changes that would allow pharmacy dispensing and/or administration of methadone that has been prescribed by a legally authorized prescriber of controlled medications who is affiliated with an OTP or is a board-certified addiction specialist physician; Regulatory (or legislative) changes that would make permanent the opioid treatment program (OTP) flexibilities, including the methadone unsupervised dosing flexibilities, implemented during the COVID-19 Public Health Emergency while continuing study of the impact of these flexibilities; Assessment of current opioid order systems and monitoring programs to more fully understand the potential negative implications for patient access to buprenorphine at pharmacies and other controlled substance medications used to treat OUD; Issuance of regulations relating to a special registration for telemedicine, as was directed in Section 3232 of the SUPPORT Act of 2018. Advocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package. Advocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers. Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs. Advocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. Supported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO). Supported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes. Joined advocacy efforts with Senate Committee on Finance, encouraging full extension of federal mental health and substance use disorder parity protections to Medicare, all of Medicaid, and TRICARE. Advocated for closer coordination among relevant federal agencies, greater integration between primary care and behavioral health reimbursement, and robust funding for the addiction treatment workforce-- such as the Addiction Medicine Fellowship Program. ASAM also expressed support for legislation to ensure state compliance with mental health and addiction parity law and codification of audio-video telehealth prescribing flexibilities for the treatment of substance use disorder. Finally, ASAM called on federal legislators to consider new and promising strategies like contingency management Urged inclusion of the field of addiction medicine in reauthorizations of several SAMHSA programs as well as conveyed ways to improve clinician access to relevant addiction medicine education Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine. Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare. Advocated for federal agency guidance on CAPTA reporting vs. notification requirements. Advocated for stronger network adequacy requirements for OTPS and addiction specialist physicians under Medicare Advantage Plans On April 4, ASAM and stakeholders sent a letter to the House Energy & Commerce Committee in support the "Mental Health Justice and Parity Act of 2022," under consideration at the Committee's April 5 hearing. The organizations asked the Committee to support the legislation that phases out "parity opt-outs" among self-funded state and local health plans. On May 10th, ASAM sent a letter to leadership of the U.S. House Committee on Energy and Commerce on H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 (the Act), in advance of the Subcommittee on Healths legislative mark-up session on May 11th. In its letter, ASAM advocates for reducing complex barriers to addiction treatment, including eliminating the one-year requirement that an individual have an addiction to opioids to begin methadone treatment at an opioid treatment program (OTP), supporting provisions inspired by the Opioid Treatment Access Act (OTAA) - including revising who can determine the stability of a patient for take-homes to include a medical practitioner appropriately licensed by the State to prescribe or dispense controlled medications, - and codifying recent mobile methadone regulations into law. In its letter, ASAM also advocates for increased funding to support HRSAs Addiction Medicine Fellowship Program; adding addiction medicine to SAMHSAs Minority Fellowship Program grants, and adding addiction specialists to HRSAs Pediatric Mental Health Care Access grants. The letter concludes with a call for adding the MATE and MAT Acts to the Act. The MATE Act would condition the federal DEA registration to prescribe controlled medications on a one-time, flexible education requirement on the treatment of patients with substance use disorder. The MAT Act would eliminate the DATA 2000-waiver, a barrier to broader uptake of treatment for OUD with buprenorphine, a life-saving medication. On April 1, ASAM joined a coalition letter to the Department of Labor and HHS expressing concern about a recent decision from a three-judge panel of the U.S. Ninth Circuit Court of Appeals that threatens to have devastating effects on Americans ability to access medically necessary mental health and substance use disorder (MH/SUD) services covered by commercial health plans and requesting that the Departments of Labor and Health and Human Services file an amicus brief in this case to support en banc review before the entire Ninth Circuit. On May 11th, ASAM and other stakeholders sent a letter to U.S. House Energy and Commerce Committee leadership praising Section 321 of the Restoring Hope for Mental Health and Well-Being Act of 2022, which would sunset the ability of self-funded, non-federal governmental health care plans to opt-out of protections provided by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. On June 3, ASAM joined a large coalition of public health, harm reduction, HIV, and hepatitis organizations in sending a letter urging Congress to appropriate $150 million in fiscal year 2023 towards the Centers for Disease Control and Preventions (CDC) Infectious Diseases and Opioid Epidemic Program. This letter garnered support from 334 organizations from all fifty states, DC, and Puerto Rico, and may be the largest display of support from community stakeholders for lifesaving harm reduction services and for ending the ban on the use of certain federal funding for syringes. On June 14th, ASAM joined a coalition letter regarding the FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill, urging House appropriators not to include provisions that would weaken FDAs authority over tobacco products. On June 27th, ASAM joined a Coalition of Whole Health letter to Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and Deputy Administrator Dr. Meena Seshamani, supporting a proposed Medicare rule that would establish a special enrollment period (SEP) for individuals formerly incarcerated and exempt those who enroll under the SEP from a Late Enrollment Penalty (LEP) and urging CMS to revise its current definition of in custody for Medicare to be consistent with the definition CMS uses for Medicaid.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · second_quarter · Budget/Appropriations
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This Program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities. Advocated for increased appropriations for HRSAs Integrated Substance Use Disorder Training Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. Advocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting underrepresented minority addiction medicine professionals, including SAMHSAs Minority Fellowship Program. Advocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and standards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings. Advocated for H.R.7803 - Michelle Alyssa Go Act, which would amend title XIX of the Social Security Act to remove the exclusion from medical assistance under the Medicaid program of items and services for patients in an institution for mental diseases, and for other purposes. Advocated for use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant and acceptance of Medicaid by treatment grantees. Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so. Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers. Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who are incarcerated, during the 30-day period preceding their release from jail or prison. Advocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which would repeal the inmate exclusion that bars the use of federal Medicaid matching funds from covering health care services in jails and prisons. Advocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of 2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates. Advocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels. Advocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA. Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares continued ability, beyond the COVID-19 public health emergency, to reimburse for audio-only, SUD and mental health telehealth services after an in-person or telehealth evaluation. Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD. Advocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment. Advocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. Advocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment: Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating Kickbacks in Recovery Act Civil, as they may be applied to the implementation of contingency management (CM) for the treatment of addiction. Approval of a prescription to over the counter (OTC) switch for at least one naloxone product. This change would save lives and reduce existing barriers that prevent access to this critical medication; Regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet level of care standards set forth in The ASAM Criteria; Regulatory (or legislative) changes that would allow pharmacy dispensing and/or administration of methadone that has been prescribed by a legally authorized prescriber of controlled medications who is affiliated with an OTP or is a board-certified addiction specialist physician; Regulatory (or legislative) changes that would make permanent the opioid treatment program (OTP) flexibilities, including the methadone unsupervised dosing flexibilities, implemented during the COVID-19 Public Health Emergency while continuing study of the impact of these flexibilities; Assessment of current opioid order systems and monitoring programs to more fully understand the potential negative implications for patient access to buprenorphine at pharmacies and other controlled substance medications used to treat OUD; Issuance of regulations relating to a special registration for telemedicine, as was directed in Section 3232 of the SUPPORT Act of 2018. Advocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package. Advocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers. Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs. Advocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. Supported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO). Supported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes. Joined advocacy efforts with Senate Committee on Finance, encouraging full extension of federal mental health and substance use disorder parity protections to Medicare, all of Medicaid, and TRICARE. Advocated for closer coordination among relevant federal agencies, greater integration between primary care and behavioral health reimbursement, and robust funding for the addiction treatment workforce-- such as the Addiction Medicine Fellowship Program. ASAM also expressed support for legislation to ensure state compliance with mental health and addiction parity law and codification of audio-video telehealth prescribing flexibilities for the treatment of substance use disorder. Finally, ASAM called on federal legislators to consider new and promising strategies like contingency management Urged inclusion of the field of addiction medicine in reauthorizations of several SAMHSA programs as well as conveyed ways to improve clinician access to relevant addiction medicine education Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine. Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare. Advocated for federal agency guidance on CAPTA reporting vs. notification requirements. Advocated for stronger network adequacy requirements for OTPS and addiction specialist physicians under Medicare Advantage Plans On April 4, ASAM and stakeholders sent a letter to the House Energy & Commerce Committee in support the "Mental Health Justice and Parity Act of 2022," under consideration at the Committee's April 5 hearing. The organizations asked the Committee to support the legislation that phases out "parity opt-outs" among self-funded state and local health plans. On May 10th, ASAM sent a letter to leadership of the U.S. House Committee on Energy and Commerce on H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 (the Act), in advance of the Subcommittee on Healths legislative mark-up session on May 11th. In its letter, ASAM advocates for reducing complex barriers to addiction treatment, including eliminating the one-year requirement that an individual have an addiction to opioids to begin methadone treatment at an opioid treatment program (OTP), supporting provisions inspired by the Opioid Treatment Access Act (OTAA) - including revising who can determine the stability of a patient for take-homes to include a medical practitioner appropriately licensed by the State to prescribe or dispense controlled medications, - and codifying recent mobile methadone regulations into law. In its letter, ASAM also advocates for increased funding to support HRSAs Addiction Medicine Fellowship Program; adding addiction medicine to SAMHSAs Minority Fellowship Program grants, and adding addiction specialists to HRSAs Pediatric Mental Health Care Access grants. The letter concludes with a call for adding the MATE and MAT Acts to the Act. The MATE Act would condition the federal DEA registration to prescribe controlled medications on a one-time, flexible education requirement on the treatment of patients with substance use disorder. The MAT Act would eliminate the DATA 2000-waiver, a barrier to broader uptake of treatment for OUD with buprenorphine, a life-saving medication. On April 1, ASAM joined a coalition letter to the Department of Labor and HHS expressing concern about a recent decision from a three-judge panel of the U.S. Ninth Circuit Court of Appeals that threatens to have devastating effects on Americans ability to access medically necessary mental health and substance use disorder (MH/SUD) services covered by commercial health plans and requesting that the Departments of Labor and Health and Human Services file an amicus brief in this case to support en banc review before the entire Ninth Circuit. On May 11th, ASAM and other stakeholders sent a letter to U.S. House Energy and Commerce Committee leadership praising Section 321 of the Restoring Hope for Mental Health and Well-Being Act of 2022, which would sunset the ability of self-funded, non-federal governmental health care plans to opt-out of protections provided by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. On June 3, ASAM joined a large coalition of public health, harm reduction, HIV, and hepatitis organizations in sending a letter urging Congress to appropriate $150 million in fiscal year 2023 towards the Centers for Disease Control and Preventions (CDC) Infectious Diseases and Opioid Epidemic Program. This letter garnered support from 334 organizations from all fifty states, DC, and Puerto Rico, and may be the largest display of support from community stakeholders for lifesaving harm reduction services and for ending the ban on the use of certain federal funding for syringes. On June 14th, ASAM joined a coalition letter regarding the FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill, urging House appropriators not to include provisions that would weaken FDAs authority over tobacco products. On June 27th, ASAM joined a Coalition of Whole Health letter to Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and Deputy Administrator Dr. Meena Seshamani, supporting a proposed Medicare rule that would establish a special enrollment period (SEP) for individuals formerly incarcerated and exempt those who enroll under the SEP from a Late Enrollment Penalty (LEP) and urging CMS to revise its current definition of in custody for Medicare to be consistent with the definition CMS uses for Medicaid.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · second_quarter · Alcohol and Drug Abuse
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This Program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities. Advocated for increased appropriations for HRSAs Integrated Substance Use Disorder Training Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. Advocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting underrepresented minority addiction medicine professionals, including SAMHSAs Minority Fellowship Program. Advocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and standards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings. Advocated for H.R.7803 - Michelle Alyssa Go Act, which would amend title XIX of the Social Security Act to remove the exclusion from medical assistance under the Medicaid program of items and services for patients in an institution for mental diseases, and for other purposes. Advocated for use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant and acceptance of Medicaid by treatment grantees. Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so. Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers. Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who are incarcerated, during the 30-day period preceding their release from jail or prison. Advocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which would repeal the inmate exclusion that bars the use of federal Medicaid matching funds from covering health care services in jails and prisons. Advocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of 2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates. Advocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels. Advocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA. Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares continued ability, beyond the COVID-19 public health emergency, to reimburse for audio-only, SUD and mental health telehealth services after an in-person or telehealth evaluation. Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD. Advocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment. Advocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. Advocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment: Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating Kickbacks in Recovery Act Civil, as they may be applied to the implementation of contingency management (CM) for the treatment of addiction. Approval of a prescription to over the counter (OTC) switch for at least one naloxone product. This change would save lives and reduce existing barriers that prevent access to this critical medication; Regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet level of care standards set forth in The ASAM Criteria; Regulatory (or legislative) changes that would allow pharmacy dispensing and/or administration of methadone that has been prescribed by a legally authorized prescriber of controlled medications who is affiliated with an OTP or is a board-certified addiction specialist physician; Regulatory (or legislative) changes that would make permanent the opioid treatment program (OTP) flexibilities, including the methadone unsupervised dosing flexibilities, implemented during the COVID-19 Public Health Emergency while continuing study of the impact of these flexibilities; Assessment of current opioid order systems and monitoring programs to more fully understand the potential negative implications for patient access to buprenorphine at pharmacies and other controlled substance medications used to treat OUD; Issuance of regulations relating to a special registration for telemedicine, as was directed in Section 3232 of the SUPPORT Act of 2018. Advocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package. Advocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers. Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs. Advocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. Supported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO). Supported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes. Joined advocacy efforts with Senate Committee on Finance, encouraging full extension of federal mental health and substance use disorder parity protections to Medicare, all of Medicaid, and TRICARE. Advocated for closer coordination among relevant federal agencies, greater integration between primary care and behavioral health reimbursement, and robust funding for the addiction treatment workforce-- such as the Addiction Medicine Fellowship Program. ASAM also expressed support for legislation to ensure state compliance with mental health and addiction parity law and codification of audio-video telehealth prescribing flexibilities for the treatment of substance use disorder. Finally, ASAM called on federal legislators to consider new and promising strategies like contingency management Urged inclusion of the field of addiction medicine in reauthorizations of several SAMHSA programs as well as conveyed ways to improve clinician access to relevant addiction medicine education Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine. Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare. Advocated for federal agency guidance on CAPTA reporting vs. notification requirements. Advocated for stronger network adequacy requirements for OTPS and addiction specialist physicians under Medicare Advantage Plans On April 4, ASAM and stakeholders sent a letter to the House Energy & Commerce Committee in support the "Mental Health Justice and Parity Act of 2022," under consideration at the Committee's April 5 hearing. The organizations asked the Committee to support the legislation that phases out "parity opt-outs" among self-funded state and local health plans. On May 10th, ASAM sent a letter to leadership of the U.S. House Committee on Energy and Commerce on H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 (the Act), in advance of the Subcommittee on Healths legislative mark-up session on May 11th. In its letter, ASAM advocates for reducing complex barriers to addiction treatment, including eliminating the one-year requirement that an individual have an addiction to opioids to begin methadone treatment at an opioid treatment program (OTP), supporting provisions inspired by the Opioid Treatment Access Act (OTAA) - including revising who can determine the stability of a patient for take-homes to include a medical practitioner appropriately licensed by the State to prescribe or dispense controlled medications, - and codifying recent mobile methadone regulations into law. In its letter, ASAM also advocates for increased funding to support HRSAs Addiction Medicine Fellowship Program; adding addiction medicine to SAMHSAs Minority Fellowship Program grants, and adding addiction specialists to HRSAs Pediatric Mental Health Care Access grants. The letter concludes with a call for adding the MATE and MAT Acts to the Act. The MATE Act would condition the federal DEA registration to prescribe controlled medications on a one-time, flexible education requirement on the treatment of patients with substance use disorder. The MAT Act would eliminate the DATA 2000-waiver, a barrier to broader uptake of treatment for OUD with buprenorphine, a life-saving medication. On April 1, ASAM joined a coalition letter to the Department of Labor and HHS expressing concern about a recent decision from a three-judge panel of the U.S. Ninth Circuit Court of Appeals that threatens to have devastating effects on Americans ability to access medically necessary mental health and substance use disorder (MH/SUD) services covered by commercial health plans and requesting that the Departments of Labor and Health and Human Services file an amicus brief in this case to support en banc review before the entire Ninth Circuit. On May 11th, ASAM and other stakeholders sent a letter to U.S. House Energy and Commerce Committee leadership praising Section 321 of the Restoring Hope for Mental Health and Well-Being Act of 2022, which would sunset the ability of self-funded, non-federal governmental health care plans to opt-out of protections provided by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. On June 3, ASAM joined a large coalition of public health, harm reduction, HIV, and hepatitis organizations in sending a letter urging Congress to appropriate $150 million in fiscal year 2023 towards the Centers for Disease Control and Preventions (CDC) Infectious Diseases and Opioid Epidemic Program. This letter garnered support from 334 organizations from all fifty states, DC, and Puerto Rico, and may be the largest display of support from community stakeholders for lifesaving harm reduction services and for ending the ban on the use of certain federal funding for syringes. On June 14th, ASAM joined a coalition letter regarding the FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill, urging House appropriators not to include provisions that would weaken FDAs authority over tobacco products. On June 27th, ASAM joined a Coalition of Whole Health letter to Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and Deputy Administrator Dr. Meena Seshamani, supporting a proposed Medicare rule that would establish a special enrollment period (SEP) for individuals formerly incarcerated and exempt those who enroll under the SEP from a Late Enrollment Penalty (LEP) and urging CMS to revise its current definition of in custody for Medicare to be consistent with the definition CMS uses for Medicaid.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · second_quarter · Insurance
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This Program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities. Advocated for increased appropriations for HRSAs Integrated Substance Use Disorder Training Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. Advocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting underrepresented minority addiction medicine professionals, including SAMHSAs Minority Fellowship Program. Advocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and standards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings. Advocated for H.R.7803 - Michelle Alyssa Go Act, which would amend title XIX of the Social Security Act to remove the exclusion from medical assistance under the Medicaid program of items and services for patients in an institution for mental diseases, and for other purposes. Advocated for use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant and acceptance of Medicaid by treatment grantees. Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so. Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers. Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who are incarcerated, during the 30-day period preceding their release from jail or prison. Advocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which would repeal the inmate exclusion that bars the use of federal Medicaid matching funds from covering health care services in jails and prisons. Advocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of 2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates. Advocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels. Advocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA. Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares continued ability, beyond the COVID-19 public health emergency, to reimburse for audio-only, SUD and mental health telehealth services after an in-person or telehealth evaluation. Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD. Advocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment. Advocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. Advocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment: Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating Kickbacks in Recovery Act Civil, as they may be applied to the implementation of contingency management (CM) for the treatment of addiction. Approval of a prescription to over the counter (OTC) switch for at least one naloxone product. This change would save lives and reduce existing barriers that prevent access to this critical medication; Regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet level of care standards set forth in The ASAM Criteria; Regulatory (or legislative) changes that would allow pharmacy dispensing and/or administration of methadone that has been prescribed by a legally authorized prescriber of controlled medications who is affiliated with an OTP or is a board-certified addiction specialist physician; Regulatory (or legislative) changes that would make permanent the opioid treatment program (OTP) flexibilities, including the methadone unsupervised dosing flexibilities, implemented during the COVID-19 Public Health Emergency while continuing study of the impact of these flexibilities; Assessment of current opioid order systems and monitoring programs to more fully understand the potential negative implications for patient access to buprenorphine at pharmacies and other controlled substance medications used to treat OUD; Issuance of regulations relating to a special registration for telemedicine, as was directed in Section 3232 of the SUPPORT Act of 2018. Advocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package. Advocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers. Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs. Advocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. Supported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO). Supported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes. Joined advocacy efforts with Senate Committee on Finance, encouraging full extension of federal mental health and substance use disorder parity protections to Medicare, all of Medicaid, and TRICARE. Advocated for closer coordination among relevant federal agencies, greater integration between primary care and behavioral health reimbursement, and robust funding for the addiction treatment workforce-- such as the Addiction Medicine Fellowship Program. ASAM also expressed support for legislation to ensure state compliance with mental health and addiction parity law and codification of audio-video telehealth prescribing flexibilities for the treatment of substance use disorder. Finally, ASAM called on federal legislators to consider new and promising strategies like contingency management Urged inclusion of the field of addiction medicine in reauthorizations of several SAMHSA programs as well as conveyed ways to improve clinician access to relevant addiction medicine education Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine. Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare. Advocated for federal agency guidance on CAPTA reporting vs. notification requirements. Advocated for stronger network adequacy requirements for OTPS and addiction specialist physicians under Medicare Advantage Plans On April 4, ASAM and stakeholders sent a letter to the House Energy & Commerce Committee in support the "Mental Health Justice and Parity Act of 2022," under consideration at the Committee's April 5 hearing. The organizations asked the Committee to support the legislation that phases out "parity opt-outs" among self-funded state and local health plans. On May 10th, ASAM sent a letter to leadership of the U.S. House Committee on Energy and Commerce on H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 (the Act), in advance of the Subcommittee on Healths legislative mark-up session on May 11th. In its letter, ASAM advocates for reducing complex barriers to addiction treatment, including eliminating the one-year requirement that an individual have an addiction to opioids to begin methadone treatment at an opioid treatment program (OTP), supporting provisions inspired by the Opioid Treatment Access Act (OTAA) - including revising who can determine the stability of a patient for take-homes to include a medical practitioner appropriately licensed by the State to prescribe or dispense controlled medications, - and codifying recent mobile methadone regulations into law. In its letter, ASAM also advocates for increased funding to support HRSAs Addiction Medicine Fellowship Program; adding addiction medicine to SAMHSAs Minority Fellowship Program grants, and adding addiction specialists to HRSAs Pediatric Mental Health Care Access grants. The letter concludes with a call for adding the MATE and MAT Acts to the Act. The MATE Act would condition the federal DEA registration to prescribe controlled medications on a one-time, flexible education requirement on the treatment of patients with substance use disorder. The MAT Act would eliminate the DATA 2000-waiver, a barrier to broader uptake of treatment for OUD with buprenorphine, a life-saving medication. On April 1, ASAM joined a coalition letter to the Department of Labor and HHS expressing concern about a recent decision from a three-judge panel of the U.S. Ninth Circuit Court of Appeals that threatens to have devastating effects on Americans ability to access medically necessary mental health and substance use disorder (MH/SUD) services covered by commercial health plans and requesting that the Departments of Labor and Health and Human Services file an amicus brief in this case to support en banc review before the entire Ninth Circuit. On May 11th, ASAM and other stakeholders sent a letter to U.S. House Energy and Commerce Committee leadership praising Section 321 of the Restoring Hope for Mental Health and Well-Being Act of 2022, which would sunset the ability of self-funded, non-federal governmental health care plans to opt-out of protections provided by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. On June 3, ASAM joined a large coalition of public health, harm reduction, HIV, and hepatitis organizations in sending a letter urging Congress to appropriate $150 million in fiscal year 2023 towards the Centers for Disease Control and Preventions (CDC) Infectious Diseases and Opioid Epidemic Program. This letter garnered support from 334 organizations from all fifty states, DC, and Puerto Rico, and may be the largest display of support from community stakeholders for lifesaving harm reduction services and for ending the ban on the use of certain federal funding for syringes. On June 14th, ASAM joined a coalition letter regarding the FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill, urging House appropriators not to include provisions that would weaken FDAs authority over tobacco products. On June 27th, ASAM joined a Coalition of Whole Health letter to Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and Deputy Administrator Dr. Meena Seshamani, supporting a proposed Medicare rule that would establish a special enrollment period (SEP) for individuals formerly incarcerated and exempt those who enroll under the SEP from a Late Enrollment Penalty (LEP) and urging CMS to revise its current definition of in custody for Medicare to be consistent with the definition CMS uses for Medicaid.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · second_quarter · Medical/Disease Research/Clinical Labs
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This Program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities. Advocated for increased appropriations for HRSAs Integrated Substance Use Disorder Training Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. Advocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting underrepresented minority addiction medicine professionals, including SAMHSAs Minority Fellowship Program. Advocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and standards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings. Advocated for H.R.7803 - Michelle Alyssa Go Act, which would amend title XIX of the Social Security Act to remove the exclusion from medical assistance under the Medicaid program of items and services for patients in an institution for mental diseases, and for other purposes. Advocated for use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant and acceptance of Medicaid by treatment grantees. Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so. Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers. Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who are incarcerated, during the 30-day period preceding their release from jail or prison. Advocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which would repeal the inmate exclusion that bars the use of federal Medicaid matching funds from covering health care services in jails and prisons. Advocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of 2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates. Advocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels. Advocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA. Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares continued ability, beyond the COVID-19 public health emergency, to reimburse for audio-only, SUD and mental health telehealth services after an in-person or telehealth evaluation. Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD. Advocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment. Advocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. Advocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment: Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating Kickbacks in Recovery Act Civil, as they may be applied to the implementation of contingency management (CM) for the treatment of addiction. Approval of a prescription to over the counter (OTC) switch for at least one naloxone product. This change would save lives and reduce existing barriers that prevent access to this critical medication; Regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet level of care standards set forth in The ASAM Criteria; Regulatory (or legislative) changes that would allow pharmacy dispensing and/or administration of methadone that has been prescribed by a legally authorized prescriber of controlled medications who is affiliated with an OTP or is a board-certified addiction specialist physician; Regulatory (or legislative) changes that would make permanent the opioid treatment program (OTP) flexibilities, including the methadone unsupervised dosing flexibilities, implemented during the COVID-19 Public Health Emergency while continuing study of the impact of these flexibilities; Assessment of current opioid order systems and monitoring programs to more fully understand the potential negative implications for patient access to buprenorphine at pharmacies and other controlled substance medications used to treat OUD; Issuance of regulations relating to a special registration for telemedicine, as was directed in Section 3232 of the SUPPORT Act of 2018. Advocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package. Advocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers. Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs. Advocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. Supported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO). Supported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes. Joined advocacy efforts with Senate Committee on Finance, encouraging full extension of federal mental health and substance use disorder parity protections to Medicare, all of Medicaid, and TRICARE. Advocated for closer coordination among relevant federal agencies, greater integration between primary care and behavioral health reimbursement, and robust funding for the addiction treatment workforce-- such as the Addiction Medicine Fellowship Program. ASAM also expressed support for legislation to ensure state compliance with mental health and addiction parity law and codification of audio-video telehealth prescribing flexibilities for the treatment of substance use disorder. Finally, ASAM called on federal legislators to consider new and promising strategies like contingency management Urged inclusion of the field of addiction medicine in reauthorizations of several SAMHSA programs as well as conveyed ways to improve clinician access to relevant addiction medicine education Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine. Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare. Advocated for federal agency guidance on CAPTA reporting vs. notification requirements. Advocated for stronger network adequacy requirements for OTPS and addiction specialist physicians under Medicare Advantage Plans On April 4, ASAM and stakeholders sent a letter to the House Energy & Commerce Committee in support the "Mental Health Justice and Parity Act of 2022," under consideration at the Committee's April 5 hearing. The organizations asked the Committee to support the legislation that phases out "parity opt-outs" among self-funded state and local health plans. On May 10th, ASAM sent a letter to leadership of the U.S. House Committee on Energy and Commerce on H.R. 7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 (the Act), in advance of the Subcommittee on Healths legislative mark-up session on May 11th. In its letter, ASAM advocates for reducing complex barriers to addiction treatment, including eliminating the one-year requirement that an individual have an addiction to opioids to begin methadone treatment at an opioid treatment program (OTP), supporting provisions inspired by the Opioid Treatment Access Act (OTAA) - including revising who can determine the stability of a patient for take-homes to include a medical practitioner appropriately licensed by the State to prescribe or dispense controlled medications, - and codifying recent mobile methadone regulations into law. In its letter, ASAM also advocates for increased funding to support HRSAs Addiction Medicine Fellowship Program; adding addiction medicine to SAMHSAs Minority Fellowship Program grants, and adding addiction specialists to HRSAs Pediatric Mental Health Care Access grants. The letter concludes with a call for adding the MATE and MAT Acts to the Act. The MATE Act would condition the federal DEA registration to prescribe controlled medications on a one-time, flexible education requirement on the treatment of patients with substance use disorder. The MAT Act would eliminate the DATA 2000-waiver, a barrier to broader uptake of treatment for OUD with buprenorphine, a life-saving medication. On April 1, ASAM joined a coalition letter to the Department of Labor and HHS expressing concern about a recent decision from a three-judge panel of the U.S. Ninth Circuit Court of Appeals that threatens to have devastating effects on Americans ability to access medically necessary mental health and substance use disorder (MH/SUD) services covered by commercial health plans and requesting that the Departments of Labor and Health and Human Services file an amicus brief in this case to support en banc review before the entire Ninth Circuit. On May 11th, ASAM and other stakeholders sent a letter to U.S. House Energy and Commerce Committee leadership praising Section 321 of the Restoring Hope for Mental Health and Well-Being Act of 2022, which would sunset the ability of self-funded, non-federal governmental health care plans to opt-out of protections provided by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. On June 3, ASAM joined a large coalition of public health, harm reduction, HIV, and hepatitis organizations in sending a letter urging Congress to appropriate $150 million in fiscal year 2023 towards the Centers for Disease Control and Preventions (CDC) Infectious Diseases and Opioid Epidemic Program. This letter garnered support from 334 organizations from all fifty states, DC, and Puerto Rico, and may be the largest display of support from community stakeholders for lifesaving harm reduction services and for ending the ban on the use of certain federal funding for syringes. On June 14th, ASAM joined a coalition letter regarding the FY 2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill, urging House appropriators not to include provisions that would weaken FDAs authority over tobacco products. On June 27th, ASAM joined a Coalition of Whole Health letter to Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and Deputy Administrator Dr. Meena Seshamani, supporting a proposed Medicare rule that would establish a special enrollment period (SEP) for individuals formerly incarcerated and exempt those who enroll under the SEP from a Late Enrollment Penalty (LEP) and urging CMS to revise its current definition of in custody for Medicare to be consistent with the definition CMS uses for Medicaid.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · second_quarter · Health Issues
H.R.7900 - National Defense Authorization Act for Fiscal Year 2023 - Provisions related to biological and chemical defense and access to Naloxone House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding. H.R.4341/S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. H.R2366/S.1457 - Stop Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $590,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
2022 · second_quarter · Homeland Security
H.R.7900 - National Defense Authorization Act for Fiscal Year 2023 - Provisions related to biological and chemical defense and access to Naloxone House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding. H.R.4341/S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. H.R2366/S.1457 - Stop Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $590,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · second_quarter · Budget/Appropriations
H.R.7900 - National Defense Authorization Act for Fiscal Year 2023 - Provisions related to biological and chemical defense and access to Naloxone House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding. H.R.4341/S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. H.R2366/S.1457 - Stop Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $590,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · second_quarter · Disaster Planning/Emergencies
H.R.7900 - National Defense Authorization Act for Fiscal Year 2023 - Provisions related to biological and chemical defense and access to Naloxone House and Senate appropriations for FY 2023 State Opioid Response (SOR) Grants funding H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding. H.R.4341/S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. H.R2366/S.1457 - Stop Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 H.R.7681 - Preventing Overdoses and Saving Lives Act 2.0 H.R.7666 - the Restoring Hope for Mental Health and Well-Being Act of 2022 S.3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $590,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · second_quarter · Health Issues
H.R. 1475/S.1795 Pursuing Equity in Mental Health Act S. 660/H.R. 2264: Tele-Mental Health Improvement Act H.R. 1364: Parity Enforcement Act S. 2086: The Resilience Investment, Support and Expansion (RISE) from Trauma Act S. 1927: Child Abuse Prevention and Treatment Act (CAPTA) Reauthorization of 2021 H.R 3467: Improving Data Collection for Adverse Childhood Experiences (ACEs) Act H.R. 1385: Behavioral Health Coordination and Communication Act S. 445: Mainstreaming Addiction Treatment Act S. 854: Methamphetamine Response Act S. 1457: STOP Fentanyl Act S. 1962/H.R. 3753: Parity Implementation Assistance Act Draft Global Enhancement of Mental Health and Psychosocial Support Access Act of 2021 H.R. 5218: Collaborate in an Orderly and Cohesive Manner Act S.2873 - Preventing and Addressing Trauma with Health Services (PATHS) Act Draft Reconciliation package Future Senate Finance Committee mental health legislation Future Cures 2.0 legislation from Rep. DeGette and Rep. Upton Draft Child Abuse and Neglect Data Collection and Improvement Act of 2021 Draft Legislation to award grants to 10 eligible crisis centers to provide follow-up services to individuals receiving suicide prevention and crisis intervention services (Rep. Trone) Coalition letter to state governors re: emergency temporary licensure waivers for out-of-state practitioners H.R. 5848 / S. 3149: Rural Health Equity Act Draft legislation to support reimbursement for psychology interns and residents in Medicare Draft legislation to support the reauthorization of Title VII programs H.R. 4026 Social Determinants of Health Data Analysis Act of 2021 H.R. 3894 CARING for Social Determinants Act of 2021 H.R. 3173 / S. 3018 Improving Seniors Access to Timely Care Act H.R. 7116 988 Implementation Act Draft bereavement care bill Letter to CDC re: Office of Rural Health Coalition thank-you letter to Congressional leadership and White House re: omnibus package S. 4301 Substance Use Prevention, Treatment, and Recovery Act S. 4306 Improving Access to Behavioral Health Integration Act S.4170 Mental Health Reform Reauthorization Act S.3824/H.R. 7073 Into the Light for MMH and SUD Act of 2022 H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022 H.R. 2955/ S. 4448 Suicide Prevention Act
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · second_quarter · Budget/Appropriations
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2022 · first_quarter · Budget/Appropriations
H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Disaster Planning/Emergencies
H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Homeland Security
H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone State Opioid Response (SOR) Grants funding H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines. HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
State Opioid Response Grants funding Substance Abuse and Mental Health Block Grant funding CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R. 2379 The State Opioid Response Grant Authorization Act of 2021 H.R 2366/S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Disaster Planning/Emergencies
H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366; S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines HR 3263 Outreach - DHS Medical Countermeasures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2022 · first_quarter · Health Issues
Lobbied for $69.5 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Lobbying to pass a fentanyl harm reduction bill called the STOP Fentanyl Act (HR 2366/S 1457) which emphasizes expanding access to health services for people who use drugs.
Client expense: $87,644 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Homeland Security
H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, H.R. 6119 - Further Extending Government Funding Act H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone. State Opioid Response (SOR) Grants funding. H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding. H.R.4341; S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. H.R2366; S.1457 - Stop Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $1,010,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · first_quarter · Budget/Appropriations
H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, H.R. 6119 - Further Extending Government Funding Act H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone. State Opioid Response (SOR) Grants funding. H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding. H.R.4341; S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. H.R2366; S.1457 - Stop Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $1,010,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · first_quarter · Health Issues
H.R. 2471 - Consolidated Appropriations Act, 2022 Appropriations funding for Fiscal Year 2022, H.R. 6119 - Further Extending Government Funding Act H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone. State Opioid Response (SOR) Grants funding. H.R.2379 - The State Opioid Response Grant Authorization Act of 2021 Substance Abuse and Mental Health Block Grant (SABG) funding. H.R.4341; S.987 - CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. H.R2366; S.1457 - Stop Fentanyl Act H.R.5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines. H.R.3263 Outreach - DHS Medical Countermeasures Act
Client expense: $1,010,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE